TipRanks
Advertisement
Advertisement

RXST Stock Latest News

RxSight price target lowered to $5.75 from $6.50 at Jefferies
The FlyRxSight price target lowered to $5.75 from $6.50 at Jefferies
20d ago
RXST
RxSight price target lowered to $5.50 from $6.50 at BofA
PremiumThe Fly
RxSight price target lowered to $5.50 from $6.50 at BofA
20d ago
RXST
RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors
PremiumCompany Announcements
RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors
2M ago
RXST
RxSight price target lowered to $7 from $8 at Stifel
PremiumThe Fly
RxSight price target lowered to $7 from $8 at Stifel
2M ago
RXST
Rxsight’s Earnings Call: Alcon Deal vs. Headwinds
PremiumCompany Announcements
Rxsight’s Earnings Call: Alcon Deal vs. Headwinds
2M ago
RXST
RxSight: Guidance Withdrawal and Strategy Reset Prompt Travis Steed to Maintain Sell Rating Amid Near-Term Execution Risks
PremiumRatingsRxSight: Guidance Withdrawal and Strategy Reset Prompt Travis Steed to Maintain Sell Rating Amid Near-Term Execution Risks
2M ago
RXST
RxSight price target raised to $6.30 from $5.50 at UBS
Premium
The Fly
RxSight price target raised to $6.30 from $5.50 at UBS
2M ago
RXST
Ryan Zimmerman Reiterates Hold on RxSight Amid Weak Core Trends and Heightened Visibility Risks
Premium
Ratings
Ryan Zimmerman Reiterates Hold on RxSight Amid Weak Core Trends and Heightened Visibility Risks
2M ago
RXST
RxSight says withdrawing guidance, will resume formal guidance in 2027
PremiumThe Fly
RxSight says withdrawing guidance, will resume formal guidance in 2027
2M ago
RXST
RxSight reports Q2 adjusted EPS (11c), consensus (19c)
PremiumThe Fly
RxSight reports Q2 adjusted EPS (11c), consensus (19c)
2M ago
RXST
RxSight resumed with a Neutral at UBS
PremiumThe Fly
RxSight resumed with a Neutral at UBS
3M ago
RXST
RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
PremiumThe Fly
RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
3M ago
RXST
TARS
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
PremiumThe FlyRxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
3M ago
RXST
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
Premium
The Fly
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
3M ago
RXST
RxSight price target lowered to $6.50 from $7.50 at Jefferies
Premium
The Fly
RxSight price target lowered to $6.50 from $7.50 at Jefferies
3M ago
RXST
RxSight price target lowered to $6.50 from $8 at BofA
PremiumThe Fly
RxSight price target lowered to $6.50 from $8 at BofA
3M ago
RXST
RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated
PremiumRatings
RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated
3M ago
RXST
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
PremiumCompany Announcements
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
3M ago
8K
RXST
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
PremiumThe Fly
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
3M ago
ALC
RXST
Alcon, RxSight announce collaboration to develop adjustable PCIOLs
PremiumThe FlyAlcon, RxSight announce collaboration to develop adjustable PCIOLs
3M ago
ALC
RXST
RxSight Stockholders Back Leadership at 2026 Annual Meeting
Premium
Company Announcements
RxSight Stockholders Back Leadership at 2026 Annual Meeting
4M ago
8K
RXST
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid
Premium
Class Action
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid
5M ago
RXST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >